AREDS2 Under Scrutiny: Advocating Unified Regulations

Age-related macular degeneration (AMD) is one of the leading causes of blindness in older adults. Dietary supplements based on the AREDS2 formulation are considered an evidence-based intervention to slow disease progression in intermediate AMD.

This study aimed to systematically compare the composition of over-the-counter dietary supplements marketed for AMD support with the original AREDS2 formula and to quantify any deviations.

As part of a market analysis, products available in Germany claiming a supportive effect in AMD were identified. The ingredients and dosages declared on the packaging were compared with the reference values used in the AREDS2 study.

The majority of analysed supplements exhibited substantial deviations from the AREDS2 formulation. On average, the concentrations of vitamin C were 52.3% lower, vitamin E 61.2% lower, and zinc 40.1% lower than the recommended amounts. Only a minority of products matched the reference formulation in both composition and dosage.

There are significant discrepancies in the composition of commercially available AREDS2-based supplements. The implementation of standardised labelling requirements and regulatory guidelines appears necessary to enhance comparability and support evidence-based use in clinical practice.